Combination Product Technology to Reach $31 Billion in 2019

March 05, 2015

Wellesley, Mass., February 05, 2015 –BCC Research (www.bccresearch.com) reveals in its new report on drug-device combination products, developments in cell-based therapeutics, progenitor cell exploitation, growth factor delivery and advanced formulation strategies are becoming the basis of even more advanced combination device strategies. Technology advancements in the drug-device combination market have been of considerable importance in recent years, and the pace of activity seems to be quickening with the appearance of many development-stage companies. The overall market is growing at a compound annual growth rate (CAGR) of 7.1% from 2014 to 2019, and thus sales are projected to reach $31 billion in 2019.

The development of the market for combination products is closely related to another dynamic and fast growing healthcare segment generally termed “drug-delivery systems.” “Delivery systems” represents a vast area of research and the demand for sophisticated drug-delivery devices is behind many novel product developments. Advanced drug-delivery devices offer increased efficiency, improved performance and convenience.

“The combination product industry is growing relatively rapidly, with particular dynamism in successful niche products. It is attracting a lot of startup capital for research and development (R&D) and developmental companies,” says BCC Research analyst Kevin Gainer. “Established products, such as drug-eluting stents, anti-microbial catheters, and photodynamic therapy, represent fairly large markets.”

It is anticipated that combination products will enable the use of therapy candidates that cannot currently be used alone due to systemic effects and toxicities. Combination product technology will enable safer and more effective technologies due to careful and precise drug targeting, local administration and individualized therapy. These have paved the way for combination products that will help patients suffering from cancer, heart disease, multiple sclerosis, cerebral palsy, spinal-cord injuries, anemia, hepatitis, rheumatoid arthritis, diabetes and other serious diseases and conditions.

The number and technological import of patents relating to products in this industry reflect the enormous efforts and expenditures to develop breakthrough therapies for serious human diseases.

Global Markets for Drug-Device Combinations analyzes the market for drug-device combination products. It provides review of technologies and products, status of R&D initiatives and a forecast of market revenues through 2019. Company profiles, clinical trials, and a patent analysis are provided as well.

                                                                           

SAMPLE FIGURE
SALES OF DRUG-DEVICE COMBINATION PRODUCTS, 2013-2019
($ BILLIONS)
SALES OF DRUG-DEVICE COMBINATION PRODUCTS, 2013-2019
To Contact us, click here  help


Source: BCC Research

Editors and reporters who wish to speak with the analyst should contact Steven Cumming at steven.cumming@bccresearch.com.

Global Markets for Drug-Device Combinations( PHM045D )
Publish Date: Dec 2014    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.